Tag Archives: AstraZeneca

UK Reacts to AZ Job Cuts

By Julian Upton | Published: February 2, 2012
UK Waits for AZ Job Cut Breakdown As this blog was posted, AstraZeneca was still keeping the world in suspense as to a further breakdown of its announced 7,300 job cuts. The company’s UK staff assembled for a meeting at 10 am, but as of lunchtime there was still no confirmation of the actual numbers , [...]
Posted in Europe | Also tagged , , | Leave a comment

First Orphan Launch a Challenge for AstraZeneca

By Ben Comer | Published: August 2, 2011
Four months after AstraZeneca received FDA approval for vandetanib, a treatment for inoperable medullary thyroid cancer, the company announced the drug’s trade name: Caprelsa. FDA said other proposed names – Zactima, for example – too closely resembled other currently marketed proprietary names. Getting FDA approval on a brand name for vandetanib, AstraZeneca’s very first orphan drug, isn’t [...]
Posted in FDA, Marketing, Safety, Strategy, patient education | Also tagged , , , , | Leave a comment

Two 'Most Promising' New Drugs Face Setbacks in US

By Ben Comer | Published: March 22, 2011
Two of the drugs named “most promising” in Thomson Reuters’ recent quarterly report hit snags in the US, despite European approval. Those two products – AstraZeneca’s Brilique (Brilinta in the US), a blood thinner, and Pharming’s Ruconest (Rhucin in the US) – were held up during FDA’s review process. Brilique (ticagrelor), AstraZeneca’s leading pipeline drug, was [...]
Posted in FDA, Global, R&D, Regulatory, Sales | Also tagged , , , , | Leave a comment

MedImmune Bets Its Fate on “Biobetters”

By Walter Armstrong | Published: September 9, 2010
AstraZeneca’s biologics shop makes a decisive move in the biosimilars market. MedImmune, the biologics shop bought by AstraZeneca (AZ) for a staggering $15 billion in 2007 promising one new drug a year for the foundering British firm, has made precious little news since the deal. But all of a sudden the post-Labor Day wires were crackling [...]
Posted in Biotech, Deals, Global, R&D, Strategy | Also tagged , , , , , | 1 Comment

Europe: Resisting the Anticompetitive Crusade

By Julian Upton | Published: July 23, 2010
It’s been another rocky few weeks for pharma in Europe. Particularly for big brand name companies. But necessity is proving the mother of invention, says Pharm Exec’s Brussels correspondent, Reflector. AstraZeneca suffered a serious setback at the start of July when the European General Court ruled that it had illegally prevented generic competition. The case dates [...]
Posted in Strategy | Also tagged , , , , , , | Leave a comment